Search results
Earnings call: Vaxart reports progress in oral vaccine development By Investing.com
Investing.com· 4 days agoThe biotechnology company, which specializes in developing oral recombinant vaccines, reported...
Earnings call: Cue Health beats Q4 revenue, plans test expansion
Investing.com· 4 days agoCue Health Inc. (NASDAQ: HLTH) exceeded its fourth quarter revenue expectations with a total of $19...
EverGlade Funding Alert - ARPA-H Seeks Revolutionary Solutions for Precision Cancer Therapy Through...
WTVO - WQRF Rockford· 17 hours agoThe Advanced Research Projects Agency for Health (ARPA-H) has officially opened the call for Solution Summaries for its Advanced Analysis for Precision cancer Therapy (ADAPT) initiative. This ...
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results
GuruFocus.com via Yahoo Finance· 4 days agoStrategic Focus and Future Outlook Vaxart's focus on developing its oral vaccine platform has been...
Moderna won’t advance US-backed Zika vaccine without more outside funding
FierceBiotech· 4 days agoModerna does not plan to advance a midstage Zika vaccine without additional outside cash, despite receiving US funding thus far, according to a regulatory disclosure. The news, tucked into Moderna ...
Bioethics in a Pandemic: Operation Warp Speed
The National Law Review· 3 days agoReferences to Operation Warp Speed (OWS) have been present throughout our coverage of the ethical questions related to the development and distribution of a COVID-19 vaccine. In fact, OWS is ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 7 days agoSIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the ...
SIGA Technologies announces 33% dividend increase
Investing.com· 7 days agoSIGA Technologies announces 33% dividend increase
BioMérieux Provides Updates on Recent 'Unprecedented Wave' of Innovation
GenomeWeb News· 4 days agoReferring to its "unprecedented wave" of innovation in 2023, BioMérieux provided extensive updates on its product lines and strategies during a call with investors Thursday morning. The French ...
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
WCMH Columbus· 4 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...